InVitae Corp (NYSE:NVTA) insider Robert L. Nussbaum sold 20,447 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $25.29, for a total value of $517,104.63. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of NYSE:NVTA traded up $0.69 on Wednesday, hitting $26.45. The company’s stock had a trading volume of 3,174,525 shares, compared to its average volume of 1,863,986. The company has a 50-day simple moving average of $24.83 and a 200 day simple moving average of $21.71. InVitae Corp has a 1 year low of $9.04 and a 1 year high of $28.75. The company has a market capitalization of $2.40 billion, a PE ratio of -13.63 and a beta of 2.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 7.18 and a quick ratio of 7.18.

InVitae (NYSE:NVTA) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.06). InVitae had a negative net margin of 83.69% and a negative return on equity of 58.48%. The business had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $50.17 million. During the same period in the previous year, the business earned ($0.47) EPS. The business’s revenue was up 43.3% on a year-over-year basis. On average, equities research analysts expect that InVitae Corp will post -2.11 earnings per share for the current fiscal year.

NVTA has been the topic of a number of recent research reports. Zacks Investment Research cut InVitae from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Leerink Swann set a $31.00 price target on InVitae and gave the company a “buy” rating in a report on Wednesday, August 7th. Oppenheimer set a $34.00 price target on InVitae and gave the company a “buy” rating in a report on Wednesday, August 7th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of InVitae in a report on Tuesday, June 11th. Finally, Benchmark reaffirmed a “buy” rating and issued a $28.00 price target (up previously from $26.00) on shares of InVitae in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $28.17.

Several large investors have recently added to or reduced their stakes in NVTA. Parallel Advisors LLC purchased a new position in shares of InVitae during the 2nd quarter valued at about $25,000. PNC Financial Services Group Inc. purchased a new position in shares of InVitae during the 1st quarter valued at about $26,000. Certified Advisory Corp purchased a new position in shares of InVitae during the 1st quarter valued at about $30,000. First Quadrant L P CA purchased a new position in shares of InVitae during the 2nd quarter valued at about $36,000. Finally, Signaturefd LLC purchased a new position in shares of InVitae during the 1st quarter valued at about $47,000. 87.51% of the stock is currently owned by hedge funds and other institutional investors.

InVitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Featured Story: What are the benefits of investing in REITs?

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.